Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective multicenter observational study of liraglutide (Rilupine) for overweight or obesity
ChiCTR2400090984Phase 4Recruiting
- Sponsor
- The First Hospital of Nanchang
- Start
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide in Overweight and obesity, sponsored by The First Hospital of Nanchang. Primary endpoint: Weight. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on ChiCTR2400090984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090984.